Though promising results have been reported with NLRP3 inhibitors for a number of conditions, toxicities and off-target effects have been a concern in some cases and small molecule NLRP3 inhibitors are less effective for CAPS-associated mutations that disrupt the binding pocket of such compounds [49, 50]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.